Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

I-Mab ADR (IMAB)

I-Mab ADR (IMAB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 659,515
  • Shares Outstanding, K 82,646
  • Annual Sales, $ 13,810 K
  • Annual Income, $ -365,870 K
  • 60-Month Beta 0.58
  • Price/Sales 47.63
  • Price/Cash Flow N/A
  • Price/Book 0.89
Trade IMAB with:

Options Overview Details

View History
  • Implied Volatility 125.45% ( -2.49%)
  • Historical Volatility 91.24%
  • IV Percentile 93%
  • IV Rank 54.54%
  • IV High 167.66% on 07/14/22
  • IV Low 74.82% on 11/12/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 11
  • Volume Avg (30-Day) 81
  • Put/Call OI Ratio 2.12
  • Today's Open Interest 2,473
  • Open Int (30-Day) 2,526

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -1.17
  • Number of Estimates 1
  • High Estimate -1.17
  • Low Estimate -1.17
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.52 +22.24%
on 08/01/22
10.82 -26.34%
on 07/28/22
-0.98 (-10.95%)
since 07/15/22
3-Month
6.52 +22.24%
on 08/01/22
13.00 -38.69%
on 05/17/22
-4.03 (-33.58%)
since 05/13/22
52-Week
6.52 +22.24%
on 08/01/22
80.88 -90.15%
on 09/07/21
-62.21 (-88.64%)
since 08/13/21

Most Recent Stories

More News
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

/PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization...

MOR : 6.08 (+2.70%)
IMAB : 7.97 (-0.13%)
Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

Genexine (KOSDAQ: 095700) a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, today announced...

IMAB : 7.97 (-0.13%)
Genexine Appoints Industry Veteran Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation

Genexine (KOSDAQ: 095700) a publicly traded, clinical stage biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, announced the...

IMAB : 7.97 (-0.13%)
OPXA : 0.97 (-9.35%)
PMN.TO : 7.50 (-2.60%)
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

IMAB and NFLX are leading out pre-market stock movers this morning

TBLT : 5.06 (-6.99%)
WWR : 1.5200 (+3.40%)
CRXT : 0.3159 (-2.05%)
IMAB : 7.97 (-0.13%)
LYRA : 6.60 (+0.92%)
I-Mab (IMAB) Sees Hammer Chart Pattern: Time to Buy?

I-Mab (IMAB) recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.

IMAB : 7.97 (-0.13%)
Reata (RETA) Plunges on FDA Concerns for Kidney Failure Drug

The FDA raises concerns related to data in Reata's (RETA) NDA seeking approval for bardoxolone for treating Alport syndrome. An advisory committee meeting is scheduled tomorrow.

VBLT : 0.2400 (-0.04%)
RETA : 20.95 (-0.33%)
ISEE : 13.48 (+3.45%)
IMAB : 7.97 (-0.13%)
Amryt (AMYT) Skin Disorder NDA Review Gets 3 Months Extension

Amryt (AMYT) is seeking approval for Oleogel-S10 for treating epidermolysis bullosa, a rare genetic skin disorder, in the United States and Europe. The FDA extends the review period for the drug's NDA...

ISEE : 13.48 (+3.45%)
IMAB : 7.97 (-0.13%)
AMYT : 7.66 (-2.30%)
INBX : 24.46 (+3.95%)
Does IMab Sponsored ADR (IMAB) Have the Potential to Rally 31% as Wall Street Analysts Expect?

The mean of analysts' price targets for IMab Sponsored ADR (IMAB) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among...

IMAB : 7.97 (-0.13%)
Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing

Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.

PFE : 49.90 (-0.42%)
NVO : 106.05 (-1.35%)
ASND : 110.23 (+5.17%)
IMAB : 7.97 (-0.13%)
MorphoSys Presents Interim Results from M-PLACE Study with Felzartamab during American Society of Nephrology Annual Meeting

Felzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathy PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November...

IMAB : 7.97 (-0.13%)
MOR : 6.08 (+2.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. I-Mab is based in SHANGHAI, China.

See More

Key Turning Points

3rd Resistance Point 8.31
2nd Resistance Point 8.18
1st Resistance Point 8.08
Last Price 7.97
1st Support Level 7.85
2nd Support Level 7.72
3rd Support Level 7.62

See More

52-Week High 80.88
Fibonacci 61.8% 52.47
Fibonacci 50% 43.70
Fibonacci 38.2% 34.93
Last Price 7.97
52-Week Low 6.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar